Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.